CompletedNCT01875822
Curcumin C-3 Complex for Schizophrenia and Related Conditions
About this title
Read the official source — NCT01875822Interventional studyAges 18–65United States
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- San JuanSee all locations and recruitment
Study information
Study start dateJune 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 17
- Sponsor
- Woodbury, Michel, M.D.
- Sponsor type
- Unknown or unclear
- Study type
- Other
- Intervention type
- Dietary supplement
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01875822
- Official title
Show the full official title
Open Label Study of Curcumin C-3 Complex, the Prototypal Epigenetic Modulator, as an Augmentation Strategy to Antipsychotic Therapy,for Improving Negative Symptoms and Cognition in Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
San Juan, Puerto Rico · United States
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Woodbury, Michel, M.D.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
